Treatment of leukemic cells with combinations of a tyrosine kinase adaphostin and proteasome inhibitors or an apoptogenic estrogen-derivative ME2 with HDACi's induce ROSs. This leads to activation of JNK, culminating in caspase activation and apoptosis.
